Science Translational Medicine · 2014 · 395 citations · 33 references
MedicineMicrobiologyOncologyCancer ImmunologyInnate ImmunityTumor ImmunologyAntitumor T Cell ResponsesBacterial SporesCancer ImmunotherapyAdaptive Antitumor ImmunityAntitumor Cytokine ResponsesAntitumor Immune ActivationClostridial SporesClostridial SporulationClostridium Perfringens SporesIntratumoral Administration
Species of Clostridium bacteria are notable for their ability to lyse tumor cells growing in hypoxic environments. We show that an attenuated strain of Clostridium novyi (C. novyi-NT) induces a microscopically precise, tumor-localized response in a rat orthotopic brain tumor model after intratumoral injection. It is well known, however, that experimental models often do not reliably predict the responses of human patients to therapeutic agents. We therefore used naturally occurring canine tumors as a translational bridge to human trials. Canine tumors are more like those of humans because they occur in animals with heterogeneous genetic backgrounds, are of host origin, and are due to spontaneous rather than engineered mutations. We found that intratumoral injection of C. novyi-NT spores was well tolerated in companion dogs bearing spontaneous solid tumors, with the most common toxicities being the expected symptoms associated with bacterial infections. Objective responses were observed in 6 of 16 dogs (37.5%), with three complete and three partial responses. On the basis of these encouraging results, we treated a human patient who had an advanced leiomyosarcoma with an intratumoral injection of C. novyi-NT spores. This treatment reduced the tumor within and surrounding the bone. Together, these results show that C. novyi-NT can precisely eradicate neoplastic tissues and suggest that further clinical trials of this agent in selected patients are warranted.
33
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations
Medicine, Oncology, Pharmacology +14
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Peter G. Isaacson, Ahmet Doǧan, Stephen K. Price et al. · The American Journal of Surgical Pathology · 1989 · 1.9K citations
Medicine, Endocrinology, Pathology +13
Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma
Siân Jones, Tian‐Li Wang, Ie‐Ming Shih et al. · Science · 2010 · 1.2K citations